

Place: CDC, 4770 Buford Highway, Chamblee Building 106 1A/1B, Atlanta, Georgia 30341.

This meeting is also accessible by teleconference and web access. Teleconference and web access login information are as follows:

Toll-Free Telephone: 1-888-972-9241, Participant passcode: 8025509.

Net Conference and Web Url: For January 28, 2016: <https://www.mymeetings.com/nc/join/>.

Conference number: PW6371280, Audience passcode: 8025509.

Participants can join the event directly at: <https://www.mymeetings.com/nc/join.php?i=PW6371280&p=8025509&t=c>.

For January 29, 2016: <https://www.mymeetings.com/nc/join/>.

Conference number: PW6371295, Audience passcode: 8025509.

Participants can join the event directly at: <https://www.mymeetings.com/nc/join.php?i=PW6371295&p=8025509&t=c>.

Status: Open to the public, limited only by the space and audio phone lines available.

Purpose: The committee provides advice and guidance to the Secretary, HHS; the Assistant Secretary for Health; and the Director, CDC, regarding the formative research, development, implementation and evaluation of evidence-based activities designed to prevent breast cancer (particularly among those at heightened risk) and promote the early detection and support of young women who develop the disease. The advice provided by the Committee will assist in ensuring scientific quality, timeliness, utility, and dissemination of credible appropriate messages and resource materials.

Matters for Discussion: The agenda will include discussions on the current and emerging topics related to breast cancer in young women. These will include public health communication, breast cancer in young women digital and social media campaigns, and CDC updates. Topics will address efforts to increase awareness around breast cancer risk, breast health, symptoms, diagnosis, and treatment of breast cancer in young women.

Agenda items are subject to change as priorities dictate.

Online Registration Required: In order to expedite the security clearance process required for entry into a Federal building, all ACBCYW attendees must register for the meeting online at least 7 business days in advance at [http://www.cdc.gov/cancer/breast/what\\_cdc\\_is\\_doing/meetings.htm](http://www.cdc.gov/cancer/breast/what_cdc_is_doing/meetings.htm). Please complete all the required fields before submitting your registration and submit no later than January 19, 2016. Each meeting day, attendees must provide CDC staff and security with driver's license/state issued ID, or passport.

Contact Person For More Information: Temeika L. Fairley, Ph.D., Designated Federal Officer, National Center for Chronic Disease Prevention and Health Promotion, CDC, 5770 Buford Hwy. NE., Mailstop K52, Atlanta, Georgia 30341, Telephone (770) 488-4518, Fax (770) 488-4760. Email: [acbcyw@cdc.gov](mailto:acbcyw@cdc.gov).

The Director, Management Analysis and Services Office, has been delegated the

authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention, and Agency for Toxic Substances and Disease Registry.

**Catherine Ramadei,**

*Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. 2015-32015 Filed 12-21-15; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Board of Scientific Counselors, National Center for Injury Prevention and Control, (BSC, NCIPC)

**AMENDMENT:** This notice was published in the **Federal Register** on December 14, 2015, Volume 80, Number 239, Page 77352. The Dial-in number should read as follows to include additional lines for public participation and to provide for people with disabilities:

Teleconference Dial-In Number: 1-888-469-1243, Participant Code: 4709506

TTY Accessible link: <http://www.captionedtext.com/client/event.aspx?CustomerID=1891&EventID=2812715>

CDC encourages participation by persons with disabilities. Captions and participation by persons with communications challenges will be available online via Relay Conference Captioning. To view the online captions at the start time of the event, please login for captioning at: <http://www.captionedtext.com/client/event.aspx?CustomerID=1891&EventID=2812715>.

Contact Person For More Information: Arlene Greenspan, DrPH, M.P.H., P.T. Associate Director for Science, NCIPC, CDC, 4770 Buford Highway NE., Mailstop F-63, Atlanta, GA 30341, Telephone (770) 488-4696.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Catherine Ramadei,**

*Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. 2015-32016 Filed 12-21-15; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Health Resources and Services Administration

#### Agency Information Collection

#### Activities: Proposed Collection: Public Comment Request

**AGENCY:** Health Resources and Services Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** In compliance with the requirement for opportunity for public comment on proposed data collection projects (Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995), the Health Resources and Services Administration (HRSA) announces plans to submit an Information Collection Request (ICR), described below, to the Office of Management and Budget (OMB). Prior to submitting the ICR to OMB, HRSA seeks comments from the public regarding the burden estimate, below, or any other aspect of the ICR.

**DATES:** Comments on this Information Collection Request must be received no later than February 19, 2016.

**ADDRESSES:** Submit your comments to [paperwork@hrsa.gov](mailto:paperwork@hrsa.gov) or mail the HRSA Information Collection Clearance Officer, Room 10-29, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857.

**FOR FURTHER INFORMATION CONTACT:** To request more information on the proposed project or to obtain a copy of the data collection plans and draft instruments, email [paperwork@hrsa.gov](mailto:paperwork@hrsa.gov) or call the HRSA Information Collection Clearance Officer at (301) 443-1984.

**SUPPLEMENTARY INFORMATION:** When submitting comments or requesting information, please include the information request collection title for reference.

#### Information Collection Request Title: HRSA National Environmental Policy Act (NEPA) Environmental Information and Documentation (EID) OMB No. 0915-0324—Extension

*Abstract:* HRSA is requesting extension of the approval for the Environmental Information and Documentation (EID) checklist which consists of information that the agency is required to obtain to comply with the National Environmental Policy Act of 1969 (NEPA). NEPA establishes the federal government's national policy for protection of the environment. HRSA has developed the EID for applicants of funding that would potentially impact the environment and to ensure that their

decision-making processes are consistent with NEPA.

**Need and Proposed Use of the Information:** Applicants must provide information and assurance of compliance with NEPA on the EID checklist. This information is reviewed in the Pre-Award stage.

**Likely Respondents:** HRSA applicants applying for federal construction grants and cooperative agreements.

**Burden Statement:** Burden in this context means the time expended by persons to generate, maintain, retain, disclose, or provide the information requested. This includes the time needed to review instructions; to develop, acquire, install, and utilize technology and systems for the purpose of collecting, validating and verifying information, processing and maintaining information, and disclosing and providing information; to train

personnel and to be able to respond to a collection of information; to search data sources; to complete and review the collection of information; and to transmit or otherwise disclose the information. The total annual burden hours estimated for this Information Collection Request are summarized in the table below.

Total Estimated Annualized burden hours:

Form name	Number of respondents	Number of responses per respondent	Total responses	Average burden per response (in hours)	Total burden hours
NEPA EID Checklist .....	1,350	1	1,350	1.0	1,350
Total .....	1,350	1	1,350	1.0	1,350

HRSA specifically requests comments on (1) the necessity and utility of the proposed information collection for the proper performance of the agency's functions, (2) the accuracy of the estimated burden, (3) ways to enhance the quality, utility, and clarity of the information to be collected, and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

**Jackie Painter,**

*Director, Division of the Executive Secretariat.*

[FR Doc. 2015-32004 Filed 12-21-15; 8:45 am]

**BILLING CODE 4165-15-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Government-Owned Inventions; Availability for Licensing**

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice

**SUMMARY:** The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

**FOR FURTHER INFORMATION CONTACT:** Licensing information and copies of the U.S. patent applications listed below may be obtained by emailing the indicated licensing contact at the

National Heart, Lung, and Blood, Office of Technology Transfer and Development Office of Technology Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479; telephone: 301-402-5579. A signed Confidential Disclosure Agreement may be required to receive copies of the patent applications.

**SUPPLEMENTARY INFORMATION:** Technology description follows.

**Metallic Nanoparticles for Photothermal Therapy**

**Description of Technology:** The invention relates to the preparation and application of 20-150nm metallic nanoparticulate vesicles for photothermal anti-cancer therapy. The vesicles comprise metallic nanoparticles covalently bound to a hydrophilic and hydrophobic polymer. The preparation method generally entails dispersing a polymer-bound metallic nanoparticle in an organic solvent, adding an aqueous solution with a dispersing aid, sonicating the mixture, and finally removing the organic solvent until the vesicle forms. The final vesicle is stable wherein the metallic nanoparticle is covalently bound to the hydrophobic and hydrophilic polymer. By way of a non-limiting example, an exemplary vesicles can be one made from gold nanorods coated with polyethylene glycol and polylactic-co-glycolic acid (AuNR@PEG/PLGA) in an oil-in-water emulsion.

**Potential Commercial Applications:**

- Cancer therapy
- Tumor therapy

**Competitive Advantages:**

- Prolonged circulation
- High tumor accumulation
- Rapid excretion
- Enhanced photoacoustic signal

- Enhanced photothermal effect/cancer therapy efficacy.

**Development Stage:**

- In vitro data

**Inventors:** Xiaoyuan (Shawn) Chen and Jibin Song (both of NIBIB).

**Intellectual Property:** HHS Reference No. E-158-2015-US-01.

- U.S. Provisional Patent Application 62/226,289 filed December 11, 2015.

**Licensing Contact:** Michael Shmilovich, Esq. CLP; 301-435-5019; [shmilovm@mail.nih.gov](mailto:shmilovm@mail.nih.gov).

**Collaborative Research Opportunity:** The National Institute of Biomedical Imaging and Bioengineering seeks statements of capability or interest from parties interested in collaborative research to further develop and evaluate metallic nanoparticle vesicles for cancer phototherapy. For collaboration opportunities, please contact Cecilia Pazman, Ph.D. at [pazmance@nhlbi.nih.gov](mailto:pazmance@nhlbi.nih.gov).

Dated: December 15, 2015.

**Michael Shmilovich,**

*Senior Licensing and Patenting Manager, National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development.*

[FR Doc. 2015-32096 Filed 12-21-15; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Prospective Grant of an Exclusive Start-Up Option License: Potent and Selective Analogues of Monamine Transporters; Methods of Making; and Uses Thereof**

**AGENCY:** National Institutes of Health, Public Health Service, HHS.